enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of human relaxin-2. We characterized how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in international registries. Methods and Results-We examined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries. Patients were considered RELAX-AHF-type if they met the following criteria: discharge diagnosis of heart failure, systolic blood pressure >125 mm Hg, dyspnea at rest or with mild exertion, intravenous diuretic use, glomerular filtration rate of 30 to 75 mL/min per 1.73 m 2 , hemoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors. Baseline characteristics and treatments of RELAX-AHF-type and non-RELAX-AHF-type patients were compared. A Cox model was used to evaluate inpatient mortality. Among both Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries, 20.7% (n=38 485) and 16.2% (n=1749) of patients met basic criteria for RELAX-AHF entry, respectively. These patients were more likely to be older, be women, have a previous history of hypertension, have preserved ejection fraction, and have better renal function. In-hospital mortality was lower in RELAX-AHF-type than in non-RELAX-AHF-type patients, even after multivariable adjustment (hazard ratio, 0.59; 95% confidence interval, 0.53-0.66; P<0.0001). 
R
andomized clinical trials (RCTs) are considered the highest standard to evaluate the therapeutic and safety efficacy of new treatments. 1 Nevertheless, trial design may dictate the selection process and recruitment of the target population, thereby affecting generalizability of trial results to a broader population. Clinical registries provide a reflection of real-world clinical practice and have become increasingly important in understanding the context and generalizability of RCT results. [2] [3] [4] As new drugs are created for the management of patients with acute heart failure (AHF), it is important to compare patients within, between, and outside RCTs. Furthermore, it is important to explore the extent of efficacy beyond the trial population and within future areas of needed research.
Drugs for the effective and safe symptom management of AHF have remained elusive. A common concern is how to target AHF populations given the extent of heterogeneity based on the marked variation in presenting symptoms, clinical characteristics, disease severity, and outcomes. Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) was a landmark international, multicenter, double-blind, placebo-controlled trial with 1161 hospitalized patients with AHF. Compared with other major AHF trials, RELAX-AHF had significantly different enrollment criteria. [5] [6] [7] [8] [9] [10] [11] In particular, RELAX-AHF investigators targeted a population with the major inclusion criteria being systolic blood pressure (SBP) >125 mm Hg (mean, 142 mm Hg) and an emphasis on early enrollment after presentation. The trial demonstrated that serelaxin, a recombinant form of human relaxin-2, significantly improved 1 of 2 primary dyspnea end points (visual analog scale, P=0.007; Likert scale, P=0.70) and reduced the risk of cardiovascular deaths and all-cause mortality at 180 days. 12 As new drugs and treatments, such as serelaxin, are discovered for the treatment of AHF, it is important to understand how trial results apply to the global AHF population.
To date, no studies have directly compared the RELAX-AHF population with a large broadly representative global registry. Therefore, we sought to characterize potentially eligible patients for RELAX-AHF in the Acute Decompensated Heart Failure National Registry-United States (ADHERE-US) and ADHERE-International (ADHERE-I) registries.
Methods

Data Sources
Data were collected retrospectively through the ADHERE-US and ADHERE-I registries. Details of both registry cohorts have been reported previously. 13, 14 Briefly, ADHERE-US enrolled 187 138 patients with AHF at 275 sites throughout the United States from January 2001 to March 2006. The ADHERE-I registry enrolled 10 904 patients with AHF at ≈70 hospitals in Asia-Pacific (Australia, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, and Thailand) and Latin America (Brazil and Mexico) from January 2006 to March 2009. Both registries include adult inpatients with a primary or secondary discharge diagnosis of acute decompensated heart failure (HF), and each site was encouraged to enroll admissions that met entry criteria as consecutively as possible. 13 Each site received approval for the study by the local institutional human research ethics committee, and patient medical records were reviewed by trained research personnel from the individual hospitals.
Study Population
The study population included data on 196 770 admissions from both ADHERE registries for patients who were hospitalized with a diagnosis of acute decompensated HF. Patients who were considered RELAX-AHF type were ≥18 years of age and met all of the following inclusion criteria: (1) discharge diagnosis of HF, (2) SBP >125 mm Hg, (3) dyspnea at rest or with mild exertion, (4) intravenous diuretic use, and (5) a glomerular filtration rate of 30 to 75 mL/min per 1.73 m 2 . Patients were excluded if they had intravenous inotropes or vasopressors during their hospital stay or hemoglobin ≤8 g/dL.
Patients not meeting all of the above criteria were considered non--RELAX-AHF-type patients.
Outcome Measures
Outcomes examined included hospital length of stay (LOS), number of days in the intensive care unit, discharge quality of care (QOC) measures, and all-cause in-hospital mortality.
Statistical Analysis
Patient sociodemographic factors, baseline characteristics, in-hospital treatment patterns, and clinical outcomes, such as LOS, were compared within ADHERE registries for patients who met RELAX-AHF clinical trial criteria versus patients who did not. Continuous variables are shown as medians with 25th and 75th percentiles and compared with a Wilcoxon rank-sum test. Categorical variables are shown as percentages and are compared with a Pearson χ 2 test. For analysis of LOS, patients transferred to another hospital were excluded. For discharge QOC measures, patients were excluded if they were discharged to hospice, left against medical advice, or transferred out.
A multivariable Cox proportional hazards model was used in the entire combined sample to evaluate the patient characteristics and region associated with in-hospital mortality within 7 days of admission. The model identifies predictors of mortality across all patients in the ADHERE registries, as well as compares the cohorts of RELAX-AHF-type and non-RELAX-AHF-type patients. In addition to region, candidate predictor variables were age, sex, current smoker, SBP, pulse, sodium, blood urea nitrogen, hemoglobin, dyspnea at rest, rales, fatigue, peripheral edema, congestion on chest radiographs, and a history of hypertension, hyperlipidemia, peripheral vascular disease, stroke or transient ischemic attack, lung disease, diabetes mellitus, anemia, coronary artery disease, HF, myocardial infarction, atrial fibrillation, or chronic renal insufficiency. A simple imputation was used to handle missing data in the model, that is, missing values were imputed to the median for continuous variables and to the dominant value for categorical variables. Continuous variables were assessed for the linearity of their relationship with risk, and modifications (such as piecewise linear splines) were made where necessary.
Stepwise selection was used to determine the set of independent predictors. Risk relationships are expressed as hazard ratios with 95% confidence intervals.
All P values were 2-sided, and a P value of <0.05 was considered statistically significant. All analyses were performed using SAS software (version 9.2, SAS Institute Inc, Cary, NC).
Results
Among 185 948 (ADHERE-US) and 10 822 (ADHERE-I) admissions with a diagnosis of AHF, 20.7% (n=38 485) and 16.2% (n=1749) of patients met RELAX-AHF major entry criteria, respectively ( Figure 1 ; Table I in the Data Supplement).
Baseline Characteristics
Among ADHERE-US, RELAX-AHF-type patients had a median age of 77 years (25th, 75th percentiles=68, 84) with 57.4% being women, whereas non-RELAX-AHF-type patients were 74 years (63, 82) and 49.9% were women ( On presentation, the RELAX-AHF-type cohort had increased reports of dyspnea, fatigue, rales, edema, and congestion on chest radiographs compared with the non-RELAX-AHF-type cohort. Notably, there were a higher percentage of patients with a history of hypertension (80.2% versus 72.5%) in the group meeting RELAX-AHF criteria. Among patients enrolled in the ADHERE-I registry, RELAX-AHF-type patients had a median age of 70 years (60, 78) and 45.3% were women, whereas non-RELAX-AHF-type patients had a median age of 67 years (55, 76) and 41.7% were women (Table 1) . Moreover, the group meeting RELAX-AHF criteria had an SBP of 150 (138, 170) and a prehospital left ventricular EF of 39% (28, 55), whereas non-RELAX-AHF-type patients had an SBP of 127 mm Hg (110, 150) and a left ventricular EF of 35% (25, 53). RELAX-AHF-type patients had lower percentages of anemia (46.1% versus 54.4%), chronic renal insufficiency (15.4% versus 23.7%), chronic hemodialysis (0.1% versus 1.5%), and implantable cardioverter-defibrillator placement (0.7% versus 2.0%), yet they had higher rates of a history of hypertension (77.2% versus 62.7%) and hyperlipidemia (47.9% versus 41.5%) compared with non-RELAX-AHF-type patients. Similar to the ADHERE-US population on presentation, the RELAX-AHF-type cohort had increased reports of dyspnea, rales, edema, and congestion on chest radiographs but similar reports of fatigue compared with the non-RELAX-AHF-type cohort.
Medications
Medications used at admission and discharge are shown in Table 2 . Notably, RELAX-AHF-type patients had significantly increased prehospital use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) in both registries but decreased use of aldosterone antagonists.
On discharge, RELAX-AHF-type patients were more often prescribed ACE inhibitors/ARBs and loop diuretics compared with their counterparts. Importantly, RELAX-AHF-type patients had a shorter median time to intravenous diuretic (United States, 2.0 hours; International, 1.7 hours) compared with non-RELAX-AHF-type patients (United States, 2.7 hours; International, 2.3 hours).
Discharge Quality of Care
Quality of care measures are reported in Table 3 
In-Hospital Procedures and Outcomes
Examining in-hospital procedures, the non-RELAX-AHFtype cohorts in both ADHERE registries had greater use of interventions, such as cardiac catheterization and mechanical ventilation (Table 3) . Overall, ADHERE-I had a longer median LOS compared with the US cohort. Non-RELAX-AHF-type patients had a longer median LOS compared with RELAX-AHF-type patients (7 versus 6 days) in ADHERE-I, whereas in ADHERE-US, the groups were similar (both 5 days). On discharge, RELAX-AHF-type patients had higher rates of being completely asymptomatic compared with non-RELAX-AHF-type patients (United States, 55.2% versus 50.8%; International, 66.5% versus 59.2%; P<0.0001); however, there were no significant differences in weight change between the 2 groups in either ADHERE-US or ADHERE-I.
Inpatient mortality rates (unadjusted) for patients hospitalized with AHF showed wide variation between RELAX types ( Table 3 ). The non-RELAX-AHF-type cohort had substantially higher inpatient mortality rates compared with the RELAX-AHF-type cohort (United States, 4.4% versus 1.6%; International, 5.7% versus 1.0%; Figure 2 ). After adjusting for baseline patient characteristics, the RELAX-AHF-type cohort had a significantly lower risk of death compared with the non-RELAX-AHF-type cohort (hazard ratio, 0.59; 95% confidence interval, 0.53-0.66; P<0.0001; Table 4 ). Higher blood urea nitrogen, greater age, extreme values (low or high) of pulse or sodium, dyspnea, congestion on chest radiographs, peripheral vascular disease, fatigue, prior history of chronic obstructive pulmonary disease or asthma, and prior stroke/transient ischemic attack were associated with an increased hazard ratio for inpatient death. Higher SBP, pulse ≈60, sodium values ≈140, hyperlipidemia, hypertension, peripheral edema, and Latin America versus other regions were associated with a lower HR for in-hospital death (Table 4) .
Non-RELAX-AHF-Type Patients
The percentages of non-RELAX-AHF-type patients meeting individual RELAX-AHF entry criteria are reported in Table 5 . Hemoglobin >8 g/dL, a principal discharge diagnosis of AHF, intravenous diuretic use, and lack of intravenous inotropes/vasopressor use had the highest percentage of patients meeting criteria in both the ADHERE-US and ADHERE-I registries. The categories with the least percentages meeting criterion included a glomerular filtration rate of 30 to 75 mL/min per 1.73 m 2 , dyspnea at rest or with mild exertion, and SBP >125 mm Hg.
Comparison of Clinical Trial Enrollees to RELAX-AHF-Type Cohort
Further analysis was performed to qualitatively characterize the clinical trial enrollees (n=1161) to the RELAX-AHF-type cohort from ADHERE registries (United States, n=38 485; International, n=1749; Table II in the Data Supplement). The RCT enrollees were found to have a relatively higher proportion of male (RCT, 63%; United States, 43%; International, 55%) and white (RCT, 95%; United States, 78%; International, 11%) patients. At baseline, the RCT population had a lower blood pressure and heart rate compared with the registry population. Comorbid conditions varied between groups, with the RCT population having lower rates of cerebrovascular disease and coronary artery disease but higher rates of hyperlipidemia and hypertension. RCT enrollees had a longer total LOS (RCT, 10.0 days; United States, 5.8 days; International, 7.9 days) and higher rates of β-blocker and ACE inhibitor/ARB use.
Discussion
Our study is 1 of the first to evaluate the representativeness of the RELAX-AHF trial population within the global AHF population. After examining 196 770 acute decompensated HF admissions in 11 countries across North America, Latin America, and Asia-Pacific, we found that ≈2 in 10 patients with AHF potentially fit RELAX-AHF major entry criteria (Figure 1 ), highlighted by SBP >125 mm Hg. Compared with non-RELAX-AHF-type patients, RELAX-AHF types were more likely to be elderly, have a history of hypertension, have preserved EF, and have better renal function, yet had fewer in-hospital procedures performed, shorter LOS, and decreased inpatient mortality. We identified important differences in processes of care for RELAX-AHF-type patients in comparison with non-RELAX-AHF-type patients. We collected data on admission and discharge medications and were able to directly compare the use of oral medications for optimal medical management of AHF. Across all groups in both registries, there was a drastic increase in the rate of ACE inhibitors/ARBs and β-blocker use from admission to discharge, which is in accordance with routine clinical practice during an AHF hospitalization in which medications are optimized. Notably, the medications prescribed the most at discharge were those with documented beneficial effect on symptoms and survival, including loop diuretics (ADHERE-US, RELAX-AHF-type: 84.8%), 15 ACE-inhibitors/ARBs (70.8%), 16 and β-blockers (65.1%) 17 ; for each medication, the RELAX-AHF-type cohort had significantly greater use compared with the non-RELAX-AHFtype cohort on discharge.
Once admitted, RELAX-AHF-type patients had shorter duration of critical care unit days compared with non-RELAX-AHF-type patients, despite a similar median total LOS. Furthermore, RELAX-AHF-type patients had significantly ACE indicates angiotensin-converting enzyme; ADHERE-I indicates Acute Decompensated Heart Failure National Registry-International; ADHERE-US, Acute Decompensated Heart Failure National Registry-United States; ARB, angiotensin receptor blocker; IV, intravenous; and RELAX-AHF-type, Relaxin for the Treatment of Acute Heart Failure-type.
better symptom status at discharge and subsequent outcomes than their counterparts (Figure 2 ), suggesting that RELAX-AHF-type patients may have more modifiable risk factors than the average AHF patient. Notably, RELAX-AHF-type patients had significantly decreased use of selected in-hospital procedures and in-hospital mortality (adjusted), which may be related to quicker median time to first intravenous AHF therapy. 18 On average, RELAX-AHF-type patients received intravenous diuretic therapy 0.6 to 0.7 hours quicker than non-RELAX-AHF-type patients, suggesting that the diagnosis of AHF was made earlier in these patients. The most striking finding came from our adjusted model, which found ACEi indicates angiotensin-converting enzyme inhibitor; ADHERE-I indicates Acute Decompensated Heart Failure National Registry-International; ADHERE-US, Acute Decompensated Heart Failure National Registry-United States; AF, atrial fibrillation; BP, blood pressure; CCU, cardiac care unit; EF, ejection fraction; HF, heart failure; ICU, intensive care unit; LVSD, left ventricular systolic dysfunction; QOC, quality of care; and RELAX-AHF-type, Relaxin for the Treatment of Acute Heart Failure-type. that RELAX-AHF-type patients had an in-hospital mortality HR of 0.59 (95% confidence interval, 0.53-0.66; P<0.0001). This could be explained by the baseline characteristics of RELAX-AHF-type patients who were not included in our model (ie, higher EF) but might be generally associated with a lower risk for clinical events. In addition, a previous history of hypertension, normalized sodium levels, and a heart rate ≈60 bpm on presentation were associated with improved outcomes in AHF as part of our risk model. Moreover, we examined the percentage of non-RELAX-AHF-type patients meeting each individual entry criterion (Table 5 ). The entry criteria such as hemoglobin >8 g/dL, principal discharge diagnosis of HF, and intravenous diuretic use, which were met by nearly every patient in either ADHERE registry, are unlikely to explain the differences between RELAX-AHF-type versus non-RELAX-AHF-type cohorts. However, criteria such as SBP >125 mm Hg, dyspnea at rest or with mild exertion, and a glomerular filtration rate of 30 to 75 mL/min per 1.73 m 2 were only met by approximately half of the non-RELAX-AHF-type patients, which may represent key discriminators between the 2 populations. In addition, these criteria may be related to the differences in outcomes between RELAX-AHF-type versus non-RELAX-AHF-type patients, and by extension, RELAX-AHF trial patients versus real-life patients with AHF.
Despite compelling clinical trial evidence and accessible national guidelines, there still remains a large treatment gap for patients with AHF. QOC initiatives provide the opportunity for performance enhancement and improvement in the use of HF therapies. 19, 20 In our study, RELAX-AHF-type patients tended to have higher rates of QOC achievement compared with non-RELAX-AHF-type patients, with the exception of smoking cessation advice. Notably, although RELAX-AHF-type patients had a statistically higher EF assessment than non-RELAX-AHF-type patients (United States, 85.8% versus 83.6%; P<0.001), this difference is not necessarily clinically meaningful given the similarity in absolute values. The largest difference between the 2 RELAX-type groups existed in prescription of ACE-inhibitors/ARBs on discharge. It is not entirely clear why RELAX-AHF-type patients would have superior QOC measures to non-RELAX-AHF-type patients, but it is likely that non-RELAX-AHF-type patients had more contraindications or prior intolerances given other clinical characteristics that confer higher risk for poorer outcomes (ie, lower blood pressure, lower effective glomerular filtration rate, etc).
In addition, we sought to qualitatively characterize these RCT enrollees on dimensions other than the specified inclusion/exclusion criteria compared with the population-based samples of patients with HF who met these criteria (Table  II in the Data Supplement) . Notably, 90% of clinical trial patients were enrolled outside of the United States, presumably accounting for some of the differences. Importantly, RCT enrollees had lower average SBP on admission and lower heart rate compared with those in the registries, likely reflecting the time of enrollment. The trial population had a longer LOS and also reflecting differences in regional enrollment.
A major question after the release of potentially paradigm-shifting results from an RCT is the degree to which the results will extend to the population of interest. The AHF population is highly heterogeneous with regard to clinical and physiological characteristics and is characterized by poor outcomes. The ADHERE registry has been shown to be representative of the real-world older HF population, as seen when ADHERE-US data were linked to fee-for-service Medicare claims. 3 Therefore, the comparison between RELAX-AHF and ADHERE populations demonstrates how results may be applicable in routine clinical practice and may help define populations of interest for studying serelaxin or other novel future AHF agents. Given that only 20% of ADHERE registry patients met major RELAX-AHF entry criteria, the question is ADHERE-I indicates Acute Decompensated Heart Failure National RegistryInternational; ADHERE-US, Acute Decompensated Heart Failure National Registry-United States; GFR, glomerular filtration rate; HF, heart failure; IV, intravenous; and RELAX-AHF, Relaxin for the Treatment of Acute Heart Failure. raised as to whether the clinical phenotype defined by RELAX-AHF basic entry criteria is a subtype population of AHF that can be distinguished from an otherwise heterogeneous group. This subtype population may not necessarily represent a different physiological process but rather the stage or severity of disease along the AHF spectrum. If serelaxin is approved for use in AHF, it will be important to recognize the population studied (in addition to those who derive the greatest benefit) and consider how to appropriately use the treatment in that population. For serelaxin, this may entail focusing on patients with a SBP >125 mm Hg early in their presentation, in addition to other key factors used in this analysis. Management of AHF has remained an ongoing clinical challenge for physicians because of its multifactorial pathogenesis and variable patient presentations. RELAX-AHF is one of the first trials in the past decade to show a reduction in mortality and long-term safety profile. Nonetheless, these findings might reflect the unique entry criteria and patient population studied. The results of RELAX-AHF will undoubtedly require replication before broader use. It will be important to understand and define the patient population that will achieve the most benefit from serelaxin or other RCT drugs. This study is the first step in subtyping patients with AHF for targeted therapies and exploring the extent of efficacy beyond the RCT population.
Our study had several limitations. First, although the ADHERE registries represent the general AHF population, the data were collected from routine clinical care, unlike that of an RCT. As a result, only major entry criteria for the RELAX-AHF study could be used for defining the potentially eligible population. Second, ADHERE pertains only to the United States, Latin America, and Asia-Pacific regions; therefore, we cannot comment on the generalizability of RELAX-AHF to European countries. Moreover, ADHERE-I represents selected sites from countries in the Asia-Pacific and Latin American regions and might not be fully representative of the regions as a whole. Third, there may be selection bias inherent to study entry at both the institutional and individual patient levels. Fourth, the ADHERE registries occurred during a different time period than the RELAX-AHF trial enrollment. Fifth, data in the ADHERE registries were collected by medical chart review and were dependent on the accuracy and completeness of documentation and abstraction. Sixth, given the large sample size in the ADHERE registries, comparisons should be treated cautiously because some statistically significant differences are small in absolute terms. Clinically meaningful comparisons should be the basis for interpretation. Seventh, the outcomes within this study are limited to the hospital stay and what was reported in the registries. Finally, there are measured and unmeasured confounding factors that may influence results.
In conclusion, the RELAX-AHF-type patient represents ≈2 in 10 patients with AHF seen in the United States, Latin America, or Asia-Pacific and exhibits better outcomes than their non-RELAX-AHF-type counterparts. This RELAX-AHF-type population is unique, and future studies or development of other therapies will be necessary for the remainder of the AHF population. As novel therapies in AHF emerge, understanding the generalizability of treatment options in patients with AHF is important for effective clinical care.
